Christopher Moxham Net Worth

The estimated Net Worth of Christopher Moxham is at least $275 Mille dollars as of 10 August 2021. Christopher Moxham owns over 51,785 units of Fulcrum Therapeutics Inc stock worth over $274,978 and over the last 4 years Christopher sold FULC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Christopher Moxham FULC stock SEC Form 4 insiders trading

Christopher has made over 1 trades of the Fulcrum Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Christopher exercised 51,785 units of FULC stock worth $405,994 on 10 August 2021.

The largest trade Christopher's ever made was exercising 51,785 units of Fulcrum Therapeutics Inc stock on 10 August 2021 worth over $405,994. On average, Christopher trades about 25,893 units every 0 days since 2021. As of 10 August 2021 Christopher still owns at least 31,071 units of Fulcrum Therapeutics Inc stock.

You can see the complete history of Christopher Moxham stock trades at the bottom of the page.

What's Christopher Moxham's mailing address?

Christopher's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Fulcrum Therapeutics Inc

Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk e Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.

What does Fulcrum Therapeutics Inc do?

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng

Complete history of Christopher Moxham stock trades at Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc executives and stock owners

Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include:

• Robert Gould,
  President, Chief Executive Officer, Director
• Owen Wallace,
  Chief Scientific Officer
• Bryan Stuart,
  Chief Operating Officer
• Dr. Judith A. Dunn Ph.D.,
  Pres of R&D and Interim Chief Medical Officer
• Bryan E. Stuart,
  Pres, CEO & Director
• Diego Cadavid,
  Senior Vice President - Clinical Development
• james Geraghty,
  Independent Director
• Kate Haviland,
  Independent Director
• Alan Ezekowitz,
  Independent Director
• James Collins,
  Independent Director
• Curtis G. Oltmans J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Mark J. Levin,
  Exec. Chairman
• Mark Levin,
  Independent Chairman of the Board
• Christina Tartaglia,
  IR Contact Officer
• Katina Dorton,
  Independent Director
• Christi Waarich,
  Director of Corp. Communications & Investor Relations
• Gregory Tourangeau,
  Controller & Principal Accounting Officer
• Esther P. Rajavelu,
  CFO & Treasurer
• Nicole T. Gallagher,
  Director of Admin.
• Peter G. Thomson,
  VP of Fin. & Accounting
• Dr. Danny Reinberg,
  Founder
• Prof. Jeannie T. Lee M.D., Ph.D.,
  Founder
• Dr. Rudolf Jaenisch M.D., Ph.D.,
  Founder
• Dr. Michael R. Green,
  Founder
• Dr. Bradley E. Bernstein M.D., Ph.D.,
  Founder
• Sonja Banks,
  
• Colin Hill,
  
• Sanofi,
  10% owner
• Rock Ventures Iii, L.P.Thir...,
  
• Dimensions Capital, L.P. 6,
  10% owner
• 32 Fund 2, Lp Section 32 Gp...,
  
• Capital, Llc Casdin Partner...,
  
• Rock Ventures Iv, L.P.Third...,
  
• Plc Gsk,
  
• Curtis Gale Oltmans,
  Chief Legal Officer
• Peter G. Thomson,
  VP Finance & Accounting
• Christopher Morabito,
  Chief Medical Officer
• Christopher Moxham,
  Chief Scientific Officer
• Judith Dunn,
  See Remarks
• Greg Tourangeau,
  Principal Accounting Officer
• Esther Rajavelu,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Alex Sapir,
  See Remarks
• Patrick Taylor Horn,
  Chief Medical Officer
• Melvin H. Iii Hayes,
  Chief Operating Officer
• Santiago Arroyo,
  Chief Medical Officer
• Capital Management, L.P.Ra ...,
  
• Alan A Musso,
  Chief Financial Officer